
|Videos|September 22, 2017
Dr. Cohen Discusses the KEYNOTE-040 Trial in Head and Neck Cancer
Author(s)Ezra Cohen, MD
Ezra Cohen, MD, associate director, Moores Cancer Center at the University of California, San Diego, discusses the phase III KEYNOTE-040 trial in head and neck cancer.
Advertisement
Ezra Cohen, MD, associate director, Moores Cancer Center at the University of California, San Diego, discusses the phase III KEYNOTE-040 trial in head and neck cancer.
The KEYNOTE-040 trial evaluated pembrolizumab (Keytruda) versus standard of care in patients with recurrent or metatstaic head and neck squamous cell carcinoma.
This was the first effort in a randomized setting to demonstrate benefit, though statistically, it did not meet its endpoint.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
The OncFive: Top Oncology Articles for the Week of 1/25
3
HPV Vaccination and Evolving Screening Strategies Continue to Shape Cervical Cancer Prevention Efforts
4
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
5



































